Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma (HYPROSAR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01904565 |
Recruitment Status : Unknown
Verified August 2015 by Prof. Dr. med. Niloy Ranjan Datta, Kantonsspital Aarau.
Recruitment status was: Recruiting
First Posted : July 22, 2013
Last Update Posted : September 2, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Soft Tissue Sarcoma | Radiation: Hyperthermia and Proton Beam | Phase 1 Phase 2 |
Hyperthermia would be delivered at Kantonsspital Aarau (KSA) with superficial or deep hyperthermia treatment units as may be appropriate. All patients would undergo a pre-hyperthermia treatment planning and a temperature of around 41.5 Centigrade to 42.5 Centigrade would be aimed during hyperthermia sessions.Hyperthermia would be delivered once a week and the treatment sessions would last for around 60 minutes of active heating.
Proton bean therapy would be carried out at Center of Proton Therapy, Paul Scherrer Institute (PSI), Villigen using scanning beam proton therapy. A preoperative dose of 55 - 60 Gray equivalent (GyE) or those considered for radical treatment, 72-76 GyE would be delivered, 5 days a week at 1.8 - 2 Gy/fr.
On days of both hyperthermia at KSA and proton therapy at PSI, the time interval between the two treatments could be 90 to 150 minutes, taking into consideration the time to travel between the two institutions. Hyperthermia in these days would follow proton beam therapy.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 26 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I/II Study of Concurrent Hyperthermia and Proton Beam Radiotherapy in Primary and Recurrent Unresectable Soft Tissue Sarcoma |
Study Start Date : | February 2014 |
Estimated Primary Completion Date : | February 2018 |
Estimated Study Completion Date : | December 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Thermoradiotherapy
Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
|
Radiation: Hyperthermia and Proton Beam
Other Names:
|
- To evaluate safety of hyperthermia and proton beam treatment in unresectable soft tissue sarcomas [ Time Frame: 6 months from end of treatment ]Acute and late morbidities of the treatment would be evaluated according to the CTCAE 4.0 guidelines during and until 6 months after the treatment
- To evaluate the local response to hyperthermia and proton beam therapy as a preoperative regimen for unresectable soft tissue sarcomaLocal control [ Time Frame: 6 months following the completion of study treatment ]Imaging response according to RECIST criteria comparing pretreatment MRI versus post treatment MRI taken 4 to 6 weeks after completion of the study treatment.
- Local disease free survival [ Time Frame: Would be assessed every 6 monthly up to a maximum of 48 months ]Local disease free survival would be computed using the Kaplan-Meir survival statistics

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histopathologically proven and classified soft tissue sarcoma (STS) as per the WHO classification (2002). For all primary tumours, biopsy would be done within 2 months prior to registration and reviewed by the study pathologist. For all recurrent tumours, if prior biopsy has been done elsewhere, the histopathology would be reviewed by the study pathologist.
-
Primary STS of extremities, trunk (except intrabdominal) and retroperitoneal which are,
- Deemed inoperable by the study surgeon
- Not feasible for a limb sparing surgery with possible R0/R1 resection as per the study surgeon,
- Patient medically unfit to undergo surgery
- Patient refuses surgery
-
Recurrent STS extremities and trunk would be eligible if
- Deemed inoperable by the study surgeon
- Not feasible for a limb sparing surgery with possible R0/R1 resection as per the study surgeon,
- Patient medically unfit to undergo surgery
- Patient refuses surgery
- Had not received prior radiotherapy to the proposed site of treatment.
- All patients having extremity STS with stages T2 and G2 or 3 with M0 (Stages IIB and III as per American Joint Committee on Cancer, AJCC 2010), would be included. For patients of STS of trunk, tumours less than 5cm may also be included if they are considered unresectable.
- Age more than 18 years
- Eastern Cooperative Oncology Group,ECOG performance scale 0 and 1
- Female patients must use effective contraception; must not be pregnant or lactating
- Life expectancy of atleast 2 years based on the age and co-morbidities, but excluding diagnosis of STS
- Absence of psychological, familial, sociological or geographical condition that could potentially hamper compliance with the study protocol and follow-up schedule
- Willing to travel to Paul Scherrer Institute for proton therapy and to Kantonsspital Aarau for Hyperthermia treatment.
- Agree to comply with the protocol
- Patients must sign a study specific informed consent form prior to registration.
Exclusion Criteria:
- Histopathology of rhabdomyosarcoma, extraosseous Ewing's, primary neuroectodermal tumour, aggressive fibromatosis (desmoids tumours), dermatofibrosarcoma protuberans, gastrointestinal stromal tumours, osteosarcoma, chondrosarcoma, Kaposi's sarcoma or angiosarcoma of scalp/face/neck
- Prior radiotherapy to the site of treatment
- Intrabdominal soft tissue sarcomas
- Use of neoadjuvant chemotherapy prior to radiotherapy or surgery
- Patients with regional nodal metastasis
- Patients with unequivocal distant metastasis
- No prior or concurrent malignancies other than surgically treated squamous cell or basal cell carcinoma of the skin which are not in the area of the present malignancy or in situ carcinoma of the skin
- No serious medical illness which would prevent informed consent or limit survival to less than 2 years
- Active uncontrolled bacterial, viral or fungal infections until these conditions are corrected or controlled.
- Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator would preclude the patient from meeting the study requirements.
- Patients having metal implants, pacemakers or clustered markers
- Patient who had a history of myocardial infarction within the past 12 months
-
No connective disease disorders that contraindicate radiotherapy, e.g., Scleroderma
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904565
Contact: Niloy R Datta, MD, DNB, | +41-62 8389559 | niloyranjan.datta@ksa.ch | |
Contact: Stephan Bodis, MD | +41-62 838 5371 | stephan.bodis@ksa.ch |
Switzerland | |
Kantonsspital Aarau | Recruiting |
Aarau, Aargau, Switzerland, CH 5001 | |
Contact: Niloy R Datta, MD, DNB, CCST 0041 62 8389559 niloyranjan.datta@ksa.ch | |
Contact: Emsad Puric, MD 0041 92 85385 Emsad.Puric@ksa.ch | |
Principal Investigator: Niloy R Datta, MD, DNB |
Principal Investigator: | Niloy R Datta, MD, DNB | Kantonsspital Aarau, Switzerland |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Prof. Dr. med. Niloy Ranjan Datta, Senior Consultant, Department of Radiation Oncology, KSA, Kantonsspital Aarau |
ClinicalTrials.gov Identifier: | NCT01904565 |
Other Study ID Numbers: |
KSA_HYPROSAR1 |
First Posted: | July 22, 2013 Key Record Dates |
Last Update Posted: | September 2, 2015 |
Last Verified: | August 2015 |
Hyperthermia, Proton beam therapy Soft Tissue Sarcoma Radiotherapy Phase I/II trial |
Sarcoma Hyperthermia Fever Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type |
Neoplasms Body Temperature Changes Heat Stress Disorders Wounds and Injuries |